Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease

This study aims to establish an integrated cohort of patients with inflammatory bowel disease (IBD) from Seoul National University Hospital, Seoul National University Boramae Medical Center, and Seoul National University Bundang Hospital. Through this cohort, we seek to develop a prognostic prediction model for IBD patients and a predictive model for therapeutic responses to biologic agents and small molecule therapies.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Crohn Disease (CD) Colitis Colitis, Ulcerative Colonic Diseases Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases IBD (Inflammatory Bowel Disease) Inflammatory Bowel Diseases Intestinal Diseases Ulcerative Colitis (UC)

Age range

10 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Hospital

Seoul, 03080, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 10 years or older who have been newly diagnosed with inflammatory bowel disease or are under follow-up monitoring.

Exclusion criteria

Patients diagnosed with cancer or with a history of cancer treatment.
Participation may be restricted at the discretion of the medical team.
Infants and young children under the age of 10.

Treatment and study plan

Primary outcomes

Prediction model in the patients with inflammatory bowel disease for treatment response

Time frame: From enrollment to the end of treatment at 12 weeks

Development of a prognostic prediction model for patients with inflammatory bowel disease and a predictive model for therapeutic response to biologic agents and small molecule therapies

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Convergence Research Platform for the Precision Medicine in the Treatment of Inflammatory Bowel Disease

Acronym: PREDICT

Important dates

Study start: 2021
Primary completion: 2026
Study completion: 2028
First posted: Sep 10, 2025
Registry last updated: Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation